Table 3.
Treatment outcome according to tumour cell type
| Tumour cell type | Survival (months), median (95 % confidence interval) | Response, n (%)a | Grade 3 or 4 toxicity, n (%) | REILD | ||
|---|---|---|---|---|---|---|
| From treatment | From diagnosis | At 3 months | At 6 months | |||
| Hepatocellular carcinoma | 8 (2.4–13.6) | 32.4 (24.9–44) | 9/15 (60) | 7/10 (70) | 10/22 (46) | 2 |
| Cholangiocarcinoma | 5.7 (2.0–9.4) | 21 (12.6–29.4) | 2/11 (18) | 2/5 (40) | 2/16 (13) | 1 |
| Neuroendocrine carcinoma | Not reached | Not reached | 8/14 (57) | 6/13 (46) | 1/19 (5) | 0 |
| Colorectal carcinoma | 10.8 (6.1–15.5) | 37.9 (30–45.8) | 5/19 (26) | 3/10 (30) | 5/28 (18) | 1 |
| Otherb | 8.3 (6–10.6) | 32.8 (18.7–46.9) | 6/15 (40) | 3/6 (50) | 6/26 (23) | 1 |
| All tumour types | 10.1 (7.4–12.8) | 37.7 (31.1–44.3) | 30/74 (41) | 21/44 (48) | 24/111 (22) | 5 |
| Evaluable patients | 122 | 122 | 74 | 44 | 111 | 111 |
| P values (between groups)c | <0.001 | <0.001 | 0.098 | 0.494 | 0.022 | NA |
REILD radioembolization-induced liver disease
aResponse includes complete response and partial response by RECIST or mRECIST, as described in the text
bTumour cell types in this group are listed in Table 1 footnote a
cLog-rank test for survival comparison between groups; nonparametric chi-squared test for response and toxicity comparison between groups